Correction: Reinvestigation of Passerini and Ugi scaffolds as multistep apoptotic inducers dual modulation of caspase 3/7 and P53-MDM2 signaling for halting breast cancer.

[This corrects the article DOI: 10.1039/D3RA04029A.].

Reinvestigation of Passerini and Ugi scaffolds as multistep apoptotic inducers dual modulation of caspase 3/7 and P53-MDM2 signaling for halting breast cancer.

Selective induction of breast cancer apoptosis is viewed as the mainstay of various ongoing oncology drug discovery programs. Passerini scaffolds have been recently exploited as selective apoptosis inducers a caspase 3/7 dependent pathway. Herein, the optimized Passerini caspase activators were manipulated to synergistically induce P53-dependent apoptosis modulating the closely related P53-MDM2 signaling axis.

Structure optimization of new tumor-selective Passerini α-acyloxy carboxamides as Caspase-3/7 activators.

Selective elimination of tumors has always been the mainstay of oncology research. The on-going research underlying the cellular apoptotic mechanisms reveal caspases activation, especially the key effector caspase-3, as a personalized tumor-selective therapeutic strategy. Our continued research protocol has exploited new optimized Passerini α-acyloxy carboxamides as efficient apoptotic inducers via caspase-3/7 dependent mechanism with highly selective anticancer profiles.

Design, synthesis and biological evaluation of novel α-acyloxy carboxamides via Passerini reaction as caspase 3/7 activators.

Evasion of apoptosis is a hallmark of cancer. Caspases; the key executors of apoptotic cascade are attractive targets for selective induction of apoptosis in cancer cells. Within this approach, various caspase activators were introduced as lead anticancer agents.